Has Ahmed Nadeem, MD received payments from drug or device companies?

Yes. Drug and device makers reported $52,829 in general payments to Ahmed Nadeem, MD across 571 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ahmed Nadeem, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ahmed Nadeem, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ahmed Nadeem, MD

Hematology & Oncology · Woonsocket, RINPI 1952332041

Payments from drug & device makers

$52,829in general payments, 2019–2025

Across 571 payments — averaging $92.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Rigel Pharmaceuticals, Inc.$22K
AstraZeneca$5K
Incyte Corporation$3K
Sirtex Medical Inc$3K
Beone Medicines USA, Inc.$2K
E.r. Squibb & Sons, L.L.C.$1K
plus $17K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Rigel Pharmaceuticals, Inc.	28	$21,864
AstraZeneca(2 entities)	46	$4,650
Incyte Corporation	22	$3,350
Sirtex Medical Inc	7	$3,057
Beone Medicines USA, Inc.	2	$1,668
E.r. Squibb & Sons, L.L.C.	34	$1,282
Puma Biotechnology, Inc.	7	$1,260
Bayer	13	$1,195
Janssen Scientific Affairs, LLC	1	$1,170
Johnson & Johnson	22	$987
GSK	25	$875
Bristol Myers Squibb	25	$862
Seagen Inc.	15	$744
AbbVie	18	$689
Eisai Inc.	12	$649
Astellas Pharma US Inc	22	$580
Beigene, Ltd.	1	$525
Novartis	22	$516
Merck	20	$463
Pfizer	27	$443
Genentech USA, Inc.	19	$423
Lilly USA, LLC	13	$381
Daiichi Sankyo Inc.	9	$347
Gilead(2 entities)	10	$275
Karyopharm Therapeutics Inc.	6	$259
Beigene USA, Inc.	6	$240
EMD Serono, Inc.	4	$221
Mirati Therapeutics, Inc.	8	$216
Jazz Pharmaceuticals Inc.	6	$214
Sobi, Inc	5	$202
Tesaro, Inc.	4	$192
Array Biopharma Inc	8	$190
Sanofi-aventis U.S. LLC	2	$167
Sanofi	7	$166
Takeda Pharmaceuticals U.S.A., Inc.	3	$164
Epizyme, Inc.	5	$157
Exelixis Inc.	6	$144
ADC Therapeutics America, Inc.	5	$137
Ipsen Biopharmaceuticals, Inc	3	$126
Amgen	5	$112
Agios Pharmaceuticals, Inc.	5	$110
TG Therapeutics, Inc.	2	$102
Comsort, Inc	1	$100
Tempus AI, Inc	2	$76
Servier Pharmaceuticals LLC	3	$74
Pharmaessentia USA Corporation	3	$72
Apellis Pharmaceuticals, Inc.	3	$72
Progenics Pharmaceuticals, Inc.	3	$70
Boehringer Ingelheim	3	$64
Pharmacyclics LLC, An Abbvie Company	3	$64
Myriad Genetic Laboratories, Inc.	3	$61
Stemline Therapeutics Inc.	2	$60
Taiho Oncology, Inc.	2	$58
Telix Pharmaceuticals	3	$55
Regeneron Healthcare Solutions, Inc.	2	$53
Alnylam Pharmaceuticals Inc.	2	$49
EUSA Pharma (US) LLC	2	$47
CTI Biopharma Corp.	2	$43
Azurity Pharmaceuticals, Inc.	2	$42
Geron Corporation	1	$33

How this compares

$52,829 in reported general payments places this provider in the 70th percentile of 68 hematology & oncology providers in Rhode Island.

See all hematology & oncology providers in Rhode Island →

Medicare billing

Part B allowed, 2024

$78,785

Medicare patients

194

Services billed

707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Woonsocket

David StollWoonsocket$154
Adam OlszewskiProvidence$7.6M
Howard SafranProvidence$4M
Alexander RaufiProvidence$1.7M
John ReaganProvidence$1.5M
Humera KhurshidProvidence$717K
Wafik El DeiryProvidence$681K
William SikovProvidence$379K
Anthony MegaProvidence$338K
Ariel BirnbaumProvidence$294K

See the full list for Rhode Island →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →